Back to Search
Start Over
DNAzyme-based therapeutics for cancer treatment.
- Source :
-
Future medicinal chemistry [Future Med Chem] 2015; Vol. 7 (13), pp. 1701-7. Date of Electronic Publication: 2015 Sep 18. - Publication Year :
- 2015
-
Abstract
- Gene-silencing strategies based on catalytic nucleic acids have been rapidly developed in the past decades. Ribozymes, antisense oligonucleotides and RNA interference have been actively pursued for years due to their potential application in gene inactivation. Pioneered by Joyce et al., a new class of catalytic nucleic acid composed of deoxyribonucleotides has emerged via an in vitro selection system. The therapeutic potential of these RNA-cleaving DNAzymes have been shown both in vitro and in vivo. Although they rival the activity and stability of synthetic ribozymes, they are limited by inefficient delivery to the intracellular targets. Recent successes in clinical testing of the DNAzymes in cancer patients have revitalized the potential clinical utility of DNAzymes.
- Subjects :
- Antineoplastic Agents chemistry
Antineoplastic Agents pharmacology
DNA, Catalytic chemistry
DNA, Catalytic pharmacology
Gene Expression Regulation drug effects
Humans
Neoplasms genetics
Neoplasms pathology
Neovascularization, Pathologic genetics
Neovascularization, Pathologic pathology
Antineoplastic Agents therapeutic use
Apoptosis drug effects
Cell Proliferation drug effects
DNA, Catalytic therapeutic use
Neoplasms drug therapy
Neovascularization, Pathologic drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1756-8927
- Volume :
- 7
- Issue :
- 13
- Database :
- MEDLINE
- Journal :
- Future medicinal chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 26381244
- Full Text :
- https://doi.org/10.4155/fmc.15.106